Related Experiment Videos
Vigabatrin in childhood epilepsy.
Journal of Child Neurology
|January 1, 1991
Summary
Vigabatrin effectively reduced seizures in children with drug-resistant epilepsy, with optimal doses between 40-80 mg/kg/day. While generally well-tolerated, some patients experienced hyperkinesia.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Drug-resistant epilepsy poses significant treatment challenges.
Purpose of the Study:
- To evaluate the long-term efficacy and tolerability of vigabatrin in children with severe drug-resistant epilepsy.
- To determine optimal dosing and identify responsive epilepsy types.
Main Methods:
- A 6-month, dose-rising study involving 66 children with severe drug-resistant epilepsy.
- Vigabatrin was added to existing antiepileptic drug regimens.
- Patients were monitored for seizure frequency, efficacy, and adverse events.
Main Results:
- 11 patients achieved seizure freedom, and 28 showed >50% seizure reduction.
- Favorable responses were seen in partial, generalized, and Lennox-Gastaut syndromes; myoclonic epilepsy showed mixed results.
- Optimal efficacy was observed at 40-80 mg/kg/day; tolerability was good, with hyperkinesia in 26% of patients.
Conclusions:
- Vigabatrin is an effective treatment option for various severe pediatric epilepsies.
- Long-term use demonstrated sustained efficacy and generally good tolerability.
- Careful monitoring for adverse effects like hyperkinesia is recommended.